Pancreatic cancer is an almost incurable malignancy whose incidence has increased over the past 30 years. Instead of pursuing the development of modalities utilizing 'traditional' cytotoxic chemotherapeutic agents, we have explored the possibilities of developing novel multi-kinase inhibitor drug combinations to kill this tumor type. Several approaches using the multi-kinase inhibitors sorafenib, regorafenib, and neratinib have been safely translated from the bench to the bedside, with objective anti-tumor responses. This review will discuss our prior preclinical and clinical studies and discuss future clinical opportunities in this disease.

中文翻译：

---

多激酶抑制剂作为胰腺癌治疗剂的开发。

胰腺癌是一种几乎无法治愈的恶性肿瘤，其发病率在过去 30 年中有所增加。我们没有追求开发利用“传统”细胞毒性化疗药物的方法，而是探索了开发新型多激酶抑制剂药物组合以杀死这种肿瘤类型的可能性。使用多激酶抑制剂索拉非尼、瑞戈非尼和来那替尼的几种方法已从工作台安全地转移到床边，具有客观的抗肿瘤反应。这篇综述将讨论我们之前的临床前和临床研究，并讨论这种疾病未来的临床机会。